drugset
drugset / Trial / NCT05818852

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

NCT05818852 ↗

Phase 1 Completed 72 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the effects of clinical and high clinical exposures of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-548 and its metabolite.

Timeline

Start
2023-04-12
Primary completion
2023-06-12
Completion
2023-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule — Oral
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.